Knoll setback helps Interneuron recover

Bad news for Knoll Pharmaceutical Co.'s Meridia anti-obesity drug helped buoy investors' confidence in Interneuron Pharmaceuticals Inc. after an FDA panel voted last week against recommending approval of Meridia.

IPIC (Lexington, Mass.), whose Redux dexfenfluramine remains the only drug approved for obesity, gained $4 on Thursday, and closed Friday at $26.25, up $0.625 for the week. The shares had fallen in advance of the meeting, aided by reports that the FDA would convene another panel to discuss the company's plans for a Phase IV study of Redux...